Syndax Pharmaceuticals (SNDX) saw its stock price drop sharply by 5.20% during Tuesday's intraday trading session. The decline comes as analysts expressed conflicting sentiments about the company's prospects in a recent report.
The healthcare sector has been under scrutiny, with analysts weighing in on various companies, including Syndax Pharmaceuticals. The mixed opinions from analysts may have contributed to investor uncertainty, leading to the significant sell-off observed in SNDX shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments